Communiqués VolitionRx Limited

Actions

VNRX

US9286612067

Recherche biotechnologique et médicale

Temps réel estimé Cboe BZX 21:56:41 22/09/2026			Varia. 5j.	Varia. 1 janv.
0,2580 ^USD	-2,60%		-10,23%	-94,92%

17/09	VolitionRx Limited apporte des précisions sur le lancement officiel du projet DETECSEPS pour le dépistage précoce du sepsis	CI
17/09	Le test Nu.Q NETs de VolitionRx Limited sélectionné comme unique biomarqueur pour la détection précoce du sepsis en France	CI

Communiqués

17/09	VolitionRx Shares Further Details and Video of the DETECSEPS Program Launch in France	PR
17/09	VolitionRx Participates in Launch of DETECSEPS Program in France	PR
14/09	VolitionRx Limited Announces Pre-Payment in Full of $7.5 million Senior Secured Convertible Promissory Note Due May 20, 2027	PR
26/08	VolitionRx Highlights Commercial Momentum and Multi-Pillar Execution Across $27+ Billion Total Addressable Markets	PR
26/08	Volition Announces Landmark Clinical Validation of Nu.Q® NETs Biomarker in Sepsis	PR
13/08	VolitionRX: Q2 Earnings Snapshot	AQ
13/08	VolitionRx : Announces Second Quarter 2026 Financial Results and Business Update	PU
12/08	Volition Demonstrates Utility of Rapid, Point-of-Care Finger-Prick Test in Sepsis Patients	PR
12/08	VolitionRx Limited Schedules Second Quarter 2026 Earnings Conference Call and Business Update	AQ
05/08	Volition Reports Publication of First Peer Reviewed Paper on New Capture-Seq™ Liquid Biopsy Technology	PR
30/07	Volition Advances Nu.Q® NETs Platform Towards Commercialization	PR
07/07	VolitionRx Announces Data Showing the Prognostic Value of its Nu.Q® Cancer Test	PR
17/06	VolitionRx Announces Collaboration with Sysmex	PR
08/06	VolitionRx Announces Pricing of $4.6 Million Public Offering	PR
03/06	VolitionRx Files New Patent Protecting its Nu.Q® NETs Test for Ebola Triage and Treatment Monitoring	PR
28/05	VolitionRx : Short Corporate Deck, May 2026	PU
28/05	VolitionRx : Corporate Presentation May 2026	PU
27/05	VolitionRx Highlights Commercial Momentum and Multi-Pillar Execution Across $27+ Billion Total Addressable Markets	PR
15/05	VolitionRx : Short Corporate Deck, May 2026	PU
15/05	VolitionRx : Corporate Presentation May 2026	PU
15/05	VolitionRX: Q1 Earnings Snapshot	AQ
14/05	VolitionRx Limited Announces First Quarter 2026 Financial Results and Business Update	PR
11/05	VolitionRx Limited Schedules First Quarter 2026 Earnings Conference Call and Business Update	PR
06/05	VolitionRx Announces Submission of Manuscript for Nu.Q® Vet Cancer Test in Cats	PR
29/04	Volition Announces Breakthrough Finger-Prick Detection of Nucleosomes; Expanding Global Market Potential for Sepsis Testing	PR